<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04586790</url>
  </required_header>
  <id_info>
    <org_study_id>oral vasopressors</org_study_id>
    <nct_id>NCT04586790</nct_id>
  </id_info>
  <brief_title>the Effect of Oral Vasopressors for Liberation From IV Vasopressors in Spinal Shock</brief_title>
  <official_title>The Effect of Oral Midodrine Versus Oral Desmopressin Acetate Use for Liberation From IV Noradrenaline in Intensive Care Unit Patients Recovering From Spinal Shock .</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ahmed talaat ahmed aly</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      the study is developed to evaluate the effect of use of oral vasopressors (midodrine versus&#xD;
      minirin) on weaning ICU patients from IV vasopressors (noradrenaline) and compare between&#xD;
      them for efficacy in shortage the duration of IV vasopressor and has low complications and&#xD;
      side effects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 15, 2020</start_date>
  <completion_date type="Anticipated">January 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>liberation the patient from IV vasopressors with maintaining hemodynamics.</measure>
    <time_frame>48 hrs</time_frame>
    <description>Blood pressure will be assessed regularly every 15 minutes</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Spinal Shock</condition>
  <arm_group>
    <arm_group_label>midodrine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>midodrine group will receive midodrine 10 mg PO q8hr with gradual weaning of IV noradrenaline after receiving 4 doses of oral midodrine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>minirin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the patients will receive minirin 60 µg PO q8hr with gradual weaning of IV noradrenaline after receiving 4 doses of oral minirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the patients will receive IV nor-adrenaline and are gradually weaning from it according to routine hospital care without adding oral midodrine or oral minirin .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midodrine Oral Tablet</intervention_name>
    <description>midodrine group will receive midodrine 10 mg PO q 8 hr with gradual weaning of IV nor-adrenaline after receiving 4 doses of oral midodrine .</description>
    <arm_group_label>midodrine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minirin oral tablet</intervention_name>
    <description>Minirin group will receive minirin 60 µg PO q 8 hr with gradual weaning of IV nor-adrenaline after receiving 4 doses of oral minirin .</description>
    <arm_group_label>minirin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nor-Adrenaline</intervention_name>
    <description>control group will receive IV nor-adrenaline and is gradually weaning from it according to routine hospital care without adding oral midodrine or oral minirin .</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age of 18 - 60 years.&#xD;
&#xD;
          -  Patients of both genders.&#xD;
&#xD;
          -  Patients diagnosed by spinal shock and they are in the recovery stage .&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient refusal.&#xD;
&#xD;
          -  Anuric or oliguric patients or patients with chronic kidney disease.&#xD;
&#xD;
          -  Patients with allergy to medication included in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed T Ahmed, lecture</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahmed T Ahmed, lecture</last_name>
    <phone>01062716629</phone>
    <email>Ahmedtalaat_ahmed@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amal A Mohamed</last_name>
    <phone>0102 175 9992</phone>
    <email>amalabdelnasser28@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ahmed Talaat Ahmed</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amal A Mohamed</last_name>
      <phone>0102 175 9992</phone>
      <email>amalabdelnasser28@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ahmed T Ahmed, lecture</last_name>
      <phone>01062716629</phone>
      <email>Ahmedtalaat_ahmed@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 7, 2020</study_first_submitted>
  <study_first_submitted_qc>October 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>October 7, 2020</last_update_submitted>
  <last_update_submitted_qc>October 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Ahmed talaat ahmed aly</investigator_full_name>
    <investigator_title>clinical professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deamino Arginine Vasopressin</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Midodrine</mesh_term>
    <mesh_term>Norepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

